Business Context and Reporting Period
This Form 8-K is a current report filed by Landec Corporation (not Lifecore Biomedical, Inc.) on November 13, 2012. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of new directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters.
Material Changes
- Board Expansion: The authorized number of directors was increased from eight (8) to ten (10).
- New Director Appointments:
- Dr. Catherine Sohn: Elected as a Class 1 Director and member of the Nominating and Corporate Governance Committee.
- Tonia Pankopf: Elected as a Class 2 Director and member of the Audit Committee.
- Compensatory Arrangements: Both new directors received identical compensation packages:
- Option to purchase 10,000 shares of Common Stock (vesting monthly over three years).
- 3,333 Restricted Stock Units (vesting fully on the third anniversary).
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It discloses that neither new director has had a material interest in any transaction exceeding $120,000 since the beginning of the last fiscal year.
Investor Verification Checklist
- Verify the correct registrant name is Landec Corporation, not Lifecore Biomedical, Inc.
- Confirm the total authorized board size is now 10 directors.
- Review the specific vesting schedules for the 10,000 stock options and 3,333 RSUs granted to Dr. Sohn and Ms. Pankopf.
- Check subsequent filings for the impact of these appointments on committee compositions.